The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQoL) profile and clinical outcomes in first-line (1L) advanced renal cell carcinoma (aRCC): A modelling analysis based on CheckMate 9ER (CM9ER) trial.
 
Jens Bedke
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Eisai; EUSA Pharma; IPSEN,; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; IPSEN,; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); IPSEN, (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Seagen (Inst)
 
Rachel H. Giles
Honoraria - IPSEN, (Inst); Merck KGaA (Inst); Pfizer/EMD Serono (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Michael Derosa
Consulting or Advisory Role - Clinical Outcomes Solutions (Inst)
 
Lysbeth Floden
Research Funding - Ipsen (Inst)
 
Intan Purnajo
No Relationships to Disclose
 
Mickael Lothgren
Employment - Ipsen
Stock and Other Ownership Interests - Amgen
 
Alessia Ogareva
Employment - IPSEN,
Stock and Other Ownership Interests - IPSEN,
Travel, Accommodations, Expenses - IPSEN, (Inst)
 
David Cella
Stock and Other Ownership Interests - FACIT.org
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Celcuity; Fulcrum Therapeutics; Immunogen; Ipsen; Novartis; Pfizer
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst); PledPharma (Inst)